IMMUNOCYTOCHEMICAL/MOLECULAR PATHOLOGY TECHNIQUES APPLIED TO CYTOPATHOLOGY

“去年，我的工作重点是 已经对几个重点的免疫细胞化学分析， 细胞学领域以及分子技术的应用 细胞病理学我一直在评估一种新的 MART 1抗体在转移性恶性肿瘤中的表达 黑色素瘤，其结果影响免疫疗法。其他 涉及MART 1的项目包括：形态学和 渗出液中黑色素瘤细胞的免疫细胞化学分析; 正常器官尸检材料和肿瘤的回顾 恶性黑色素瘤的鉴别诊断，以评估MART 1 非黑色素瘤性HMB 45阳性 肿瘤比较MART-1染色; MART-1比较 HMB 45在恶性黑色素瘤FNA标本中的表达。 这些研究对于描述这种新的 抗体的我参与了使用显微切割和PCR 用于检测原发性和FNA中的特异性等位基因缺失， 转移性肾细胞癌，以证明在肿瘤与 已知的遗传改变这些技术可用于 通过与对照组比较， 原发性肿瘤和正常组织。我们也在利用这些 在选定的细胞学样本中， 通过使用形态学来积极识别， 免疫细胞化学，看看恶性肿瘤的明确诊断 可以通过PCR分析不同的细胞群 与原发性肿瘤相比。最近，我 开始了一个项目，再次采用显微切割和PCR， FNA用于评价P16的洛以及 PCR分析所需的细胞计数。最近， 应用显微切割和PCR技术检测了10例正常人和10例正常人的洛合性缺失， 良性和恶性肾上腺组织/肿瘤的FNA， 希望利用对特定遗传异常的分析， FNA对肾上腺病变的诊断价值。 VHL基因"

"Discontinued In the last year, the focus of my work has been on the immunocytochemical analyses of several focused areas of cytology, as well as the application of molecular techniques to cytopathology. I have been evaluating the expression of a new antibody, MART1, for it's expression in metastatic malignant melanoma, the results of which impacts on immunotherapy. Other projects involving MART1 include: the morphologic and immunocytochemical analysis of melanoma cells in effusions; a review of normal organ autopsy material and neoplasms in the differential diagnosis of malignant melanoma to evaluate MART1 expression; a review of non-melanomatous HMB45 positive neoplasms to compare MART1 staining; a comparision of MART-1 to HMB45 expression in FNA material of Malignant melanomas. These studies are important for the characterizations of this new antibody. I have been involved in using microdissection and PCR for the detection of specific allelic loss in primary and FNAs of metastatic renal cell carcinomas, to prove that in tumors with known genetic alterations these techniques can be used for the positive identification of metastatic lesions by comparison with the primary neoplasm and normal tissue. We are also using these techniques in selected cytologic samples with cells that are difficult to identify positively through the use of morphology and immunocytochemistry, to see if a definitive diagnosis of malignancy can be made through the PCR analysis of different cell populations with comparison to the primary neoplasm. Most recently, I have begun a project, again employing microdissection and PCR, in FNAs of melanoma for the evaluation of LOH for P16 as well as enumeration of cells required forPCR analysis.Most recently we have applied microdissection and PCR for the detection of LOH in FNAs of benign and malignant adrenal tissue/neoplasms, in the hopes of utilizing analyses of specific genetic abnormalities for the diagnosis of adrenal lesions on FNA.Loci studied wer p53, 1p and the VHL gene."